The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells - PubMed (original) (raw)
. 2001 Oct 1;61(19):7184-8.
Affiliations
- PMID: 11585753
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
M M Moasser et al. Cancer Res. 2001.
Abstract
The epidermal growth factor receptor (EGFR) is commonly overexpressed in many human tumors and provides a new target for anticancer drug development. ZD1839 ("Iressa"), a quinazoline tyrosine kinase inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials. However, because it remains unclear which tumor types are the best targets for treatment with this agent, the molecular characteristics that correlate with tumor sensitivity to ZD1839 have been studied. In a panel of human breast cancer and other epithelial tumor cell lines, HER2-overexpressing tumors were particularly sensitive to ZD1839. Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with phosphatidylinositol 3-kinase, and down-regulation of Akt activity. These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family tyrosine kinase signaling and suggest novel strategies to treat these particularly aggressive tumors.
Similar articles
- Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Viganò L, Fumagalli M, Ménard S, Gianni L. Campiglio M, et al. J Cell Physiol. 2004 Feb;198(2):259-68. doi: 10.1002/jcp.10411. J Cell Physiol. 2004. PMID: 14603528 - HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, Kuwano M, Ono M. Hirata A, et al. Cancer Res. 2005 May 15;65(10):4253-60. doi: 10.1158/0008-5472.CAN-04-2748. Cancer Res. 2005. PMID: 15899817 - Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N, Maiello MR, De Luca A. Normanno N, et al. J Cell Physiol. 2003 Jan;194(1):13-9. doi: 10.1002/jcp.10194. J Cell Physiol. 2003. PMID: 12447985 Review.
Cited by
- Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications.
Shaban N, Kamashev D, Emelianova A, Buzdin A. Shaban N, et al. Cells. 2023 Dec 25;13(1):47. doi: 10.3390/cells13010047. Cells. 2023. PMID: 38201251 Free PMC article. Review. - Busting the Breast Cancer with AstraZeneca's Gefitinib.
Chemmalar S, Intan Shameha AR, Che Abdullah CA, Ab Razak NA, Yusof LM, Ajat M, Chan KW, Abu Bakar Zakaria MZ. Chemmalar S, et al. Adv Pharmacol Pharm Sci. 2023 Dec 4;2023:8127695. doi: 10.1155/2023/8127695. eCollection 2023. Adv Pharmacol Pharm Sci. 2023. PMID: 38090376 Free PMC article. Review. - From Therapy Resistance to Targeted Therapies in Prostate Cancer.
Moreira-Silva F, Henrique R, Jerónimo C. Moreira-Silva F, et al. Front Oncol. 2022 May 24;12:877379. doi: 10.3389/fonc.2022.877379. eCollection 2022. Front Oncol. 2022. PMID: 35686097 Free PMC article. Review. - Small Molecules Targeting Programmed Cell Death in Breast Cancer Cells.
Maniam S, Maniam S. Maniam S, et al. Int J Mol Sci. 2021 Sep 8;22(18):9722. doi: 10.3390/ijms22189722. Int J Mol Sci. 2021. PMID: 34575883 Free PMC article. Review. - Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?
Mollaei M, Hassan ZM, Khorshidi F, Langroudi L. Mollaei M, et al. Transl Oncol. 2021 May;14(5):101056. doi: 10.1016/j.tranon.2021.101056. Epub 2021 Mar 6. Transl Oncol. 2021. PMID: 33684837 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous